FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2028995090> ?p ?o ?g. }

• W2028995090 endingPage "18" @default.
• W2028995090 startingPage "9" @default.
• W2028995090 abstract "OBJECTIVES: To evaluate the efficacy and safety of efalizumab in continuous or interrupted therapy of adults with moderate-to-severe plaque psoriasis who had failed to respond to or were intolerant of other systemic therapies, including methotrexate, ciclosporin and psoralen plus UVA phototherapy, or for whom such therapies were contraindicated. METHODS: Patients received a conditioning dose of efalizumab 0.7 mg/kg followed by once-weekly open-label efalizumab 1.0 mg/kg for 11 weeks. Responders (Physician Global Assessment [PGA] score of good or better at Week 12) could continue efalizumab for a further 8 weeks (continuous-treatment period). Nonresponders transitioned to alternative anti-psoriasis medication or stopped treatment. Responders who discontinued efalizumab could restart treatment if symptoms worsened. PGA response was evaluated at Weeks 12 (primary endpoint) and 20, as were the proportions of patients achieving an improvement from baseline of >/=50%, >/=75% and >/=90% in Psoriasis Area and Severity Index (PASI) (PASI 50, PASI 75 and PASI 90, respectively). RESULTS: A total of 1,255 patients were included in the intention-to-treat population. At Week 12, 68.0% of patients had a PGA rating of good or better. Of 688 patients who entered the continuous-treatment period, 79.5% had a PGA rating of good or better at Week 20. At Week 12, median improvement in PASI score was 68.4%. PASI 50/75/90 was achieved by 65.5%/35.9%/13.0% of patients at Week 12, and by 78.2%/52.9%/24.3% of responders at Week 20. Of the 127 responders at Week 12 who discontinued efalizumab, 11% experienced rebound and 56.7% relapsed within 8 weeks after stopping therapy. Efalizumab was well tolerated during the study. CONCLUSIONS: Efalizumab provided effective control of psoriasis in the majority of patients during the initial treatment period. The high response rates were maintained in initial responders when treatment was continued beyond 12 weeks." @default.
• W2028995090 created "2016-06-24" @default.
• W2028995090 creator A5004446285 @default.
• W2028995090 creator A5013061543 @default.
• W2028995090 creator A5043220171 @default.
• W2028995090 creator A5046678173 @default.
• W2028995090 creator A5057810306 @default.
• W2028995090 creator A5065244911 @default.
• W2028995090 creator A5065367798 @default.
• W2028995090 date "2010-03-01" @default.
• W2028995090 modified "2023-09-30" @default.
• W2028995090 title "Efficacy and Safety of Efalizumab in Patients with Moderate-to-Severe Plaque Psoriasis Resistant to Previous Anti-Psoriatic Treatment: Results of a Multicentre, Open-label, Phase IIIb/IV Trial" @default.
• W2028995090 cites W2023639945 @default.
• W2028995090 cites W2034585843 @default.
• W2028995090 cites W2036488279 @default.
• W2028995090 cites W2058050795 @default.
• W2028995090 cites W2067327580 @default.
• W2028995090 cites W2121126920 @default.
• W2028995090 cites W2125750090 @default.
• W2028995090 cites W2129137973 @default.
• W2028995090 cites W2152106583 @default.
• W2028995090 cites W2152976783 @default.
• W2028995090 cites W2169787227 @default.
• W2028995090 doi "https://doi.org/10.1111/j.1753-5174.2009.00026.x" @default.
• W2028995090 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2855833" @default.
• W2028995090 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20428228" @default.
• W2028995090 hasPublicationYear "2010" @default.
• W2028995090 type Work @default.
• W2028995090 sameAs 2028995090 @default.
• W2028995090 citedByCount "11" @default.
• W2028995090 countsByYear W20289950902014 @default.
• W2028995090 countsByYear W20289950902015 @default.
• W2028995090 countsByYear W20289950902016 @default.
• W2028995090 countsByYear W20289950902017 @default.
• W2028995090 countsByYear W20289950902018 @default.
• W2028995090 crossrefType "journal-article" @default.
• W2028995090 hasAuthorship W2028995090A5004446285 @default.
• W2028995090 hasAuthorship W2028995090A5013061543 @default.
• W2028995090 hasAuthorship W2028995090A5043220171 @default.
• W2028995090 hasAuthorship W2028995090A5046678173 @default.
• W2028995090 hasAuthorship W2028995090A5057810306 @default.
• W2028995090 hasAuthorship W2028995090A5065244911 @default.
• W2028995090 hasAuthorship W2028995090A5065367798 @default.
• W2028995090 hasBestOaLocation W20289950901 @default.
• W2028995090 hasConcept C126322002 @default.
• W2028995090 hasConcept C141071460 @default.
• W2028995090 hasConcept C16005928 @default.
• W2028995090 hasConcept C197934379 @default.
• W2028995090 hasConcept C2777011040 @default.
• W2028995090 hasConcept C2780564577 @default.
• W2028995090 hasConcept C2780969348 @default.
• W2028995090 hasConcept C2908647359 @default.
• W2028995090 hasConcept C3020604521 @default.
• W2028995090 hasConcept C71924100 @default.
• W2028995090 hasConcept C99454951 @default.
• W2028995090 hasConceptScore W2028995090C126322002 @default.
• W2028995090 hasConceptScore W2028995090C141071460 @default.
• W2028995090 hasConceptScore W2028995090C16005928 @default.
• W2028995090 hasConceptScore W2028995090C197934379 @default.
• W2028995090 hasConceptScore W2028995090C2777011040 @default.
• W2028995090 hasConceptScore W2028995090C2780564577 @default.
• W2028995090 hasConceptScore W2028995090C2780969348 @default.
• W2028995090 hasConceptScore W2028995090C2908647359 @default.
• W2028995090 hasConceptScore W2028995090C3020604521 @default.
• W2028995090 hasConceptScore W2028995090C71924100 @default.
• W2028995090 hasConceptScore W2028995090C99454951 @default.
• W2028995090 hasIssue "1" @default.
• W2028995090 hasLocation W20289950901 @default.
• W2028995090 hasLocation W20289950902 @default.
• W2028995090 hasLocation W20289950903 @default.
• W2028995090 hasLocation W20289950904 @default.
• W2028995090 hasOpenAccess W2028995090 @default.
• W2028995090 hasPrimaryLocation W20289950901 @default.
• W2028995090 hasRelatedWork W1975210221 @default.
• W2028995090 hasRelatedWork W2027334126 @default.
• W2028995090 hasRelatedWork W2030458038 @default.
• W2028995090 hasRelatedWork W204496304 @default.
• W2028995090 hasRelatedWork W2144202131 @default.
• W2028995090 hasRelatedWork W2398457950 @default.
• W2028995090 hasRelatedWork W2404038155 @default.
• W2028995090 hasRelatedWork W4253114135 @default.
• W2028995090 hasRelatedWork W80953640 @default.
• W2028995090 hasRelatedWork W1967057698 @default.
• W2028995090 hasVolume "3" @default.
• W2028995090 isParatext "false" @default.
• W2028995090 isRetracted "false" @default.
• W2028995090 magId "2028995090" @default.
• W2028995090 workType "article" @default.